drugset / Trial / NCT00161655

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

NCT00161655

Phase 4 Completed 60 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

Timeline

Start
2005-04
Primary completion
2006-08
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic
Subject Methotrexate Small molecule